Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 355

1.

The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors.

Kopp RP, Marshall LM, Wang PY, Bauer DC, Barrett-Connor E, Parsons JK; Osteoporotic Fractures in Men MrOS Research Group.

Eur Urol. 2013 Oct;64(4):672-9. doi: 10.1016/j.eururo.2013.03.041. Epub 2013 Apr 3.

2.

Re: The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors.

Griebling TL.

J Urol. 2014 Apr;191(4):1056. doi: 10.1016/j.juro.2014.01.058. Epub 2014 Jan 17. No abstract available.

PMID:
24703136
3.

Re: The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors.

Taneja SS.

J Urol. 2013 Nov;190(5):1763-4. doi: 10.1016/j.juro.2013.07.082. Epub 2013 Aug 2. No abstract available.

PMID:
24120777
4.

Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.

Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR.

Eur Urol. 2015 Oct;68(4):600-8. doi: 10.1016/j.eururo.2014.08.074. Epub 2014 Sep 18.

5.

Degree of preservation of the neurovascular bundles during radical prostatectomy and urinary continence 1 year after surgery.

Steineck G, Bjartell A, Hugosson J, Axén E, Carlsson S, Stranne J, Wallerstedt A, Persson J, Wilderäng U, Thorsteinsdottir T, Gustafsson O, Lagerkvist M, Jiborn T, Haglind E, Wiklund P; LAPPRO steering committee.

Eur Urol. 2015 Mar;67(3):559-68. doi: 10.1016/j.eururo.2014.10.011. Epub 2014 Oct 28.

PMID:
25457018
6.

Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the Osteoporotic Fractures in Men study.

Parsons JK, Messer K, White M, Barrett-Connor E, Bauer DC, Marshall LM; Osteoporotic Fractures in Men (MrOS) Research Group and the Urologic Diseases in America Project.

Eur Urol. 2011 Dec;60(6):1173-80. doi: 10.1016/j.eururo.2011.07.040. Epub 2011 Jul 23.

7.

Long-term effects of androgen deprivation therapy in prostate cancer patients.

Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS.

Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86.

PMID:
12072048
8.

Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.

Stattin P, Sandin F, Thomsen FB, Garmo H, Robinson D, Lissbrant IF, Jonsson H, Bratt O.

Eur Urol. 2017 Jul;72(1):125-134. doi: 10.1016/j.eururo.2016.07.023. Epub 2016 Aug 5.

9.

Psychological resilience aspects that mediate the depressive effects of urinary incontinence in prostate cancer survivors 10 years after treatment with radiation and hormone ablation.

Sharpley CF, Bitsika V, Christie DRH, Bradford R, Steigler A, Denham JW.

J Psychosoc Oncol. 2017 Jul-Aug;35(4):438-450. doi: 10.1080/07347332.2017.1306733. Epub 2017 Mar 20.

PMID:
28318448
10.

Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

Eur Urol. 2013 Jul;64(1):159-66. doi: 10.1016/j.eururo.2012.04.035. Epub 2012 Apr 19.

11.

Population-based study of long-term functional outcomes after prostate cancer treatment.

Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, Johansson E, Stattin P, Fransson P.

BJU Int. 2016 Jun;117(6B):E36-45. doi: 10.1111/bju.13179. Epub 2015 Jun 23.

12.

Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.

O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M.

J Clin Oncol. 2015 Apr 10;33(11):1243-51. doi: 10.1200/JCO.2014.59.1792. Epub 2015 Mar 2.

PMID:
25732167
13.

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S.

J Clin Oncol. 2006 Aug 20;24(24):3979-83.

PMID:
16921050
14.

Impact of age on quality-of-life outcomes after treatment for localized prostate cancer.

Hampson LA, Cowan JE, Zhao S, Carroll PR, Cooperberg MR.

Eur Urol. 2015 Sep;68(3):480-6. doi: 10.1016/j.eururo.2015.01.008. Epub 2015 Feb 2.

15.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

PMID:
17925537
17.

Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.

Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL.

Eur Urol. 2012 Jun;61(6):1119-28. doi: 10.1016/j.eururo.2012.01.045. Epub 2012 Feb 1.

18.

A Population-based Survey of the Prevalence, Potential Risk Factors, and Symptom-specific Bother of Lower Urinary Tract Symptoms in Adult Chinese Women.

Zhang L, Zhu L, Xu T, Lang J, Li Z, Gong J, Liu Q, Liu X.

Eur Urol. 2015 Jul;68(1):97-112. doi: 10.1016/j.eururo.2014.12.012. Epub 2015 Jan 5.

PMID:
25572826
19.

Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients.

Crouzet S, Chapelon JY, Rouvière O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, Martin X, Gelet A.

Eur Urol. 2014 May;65(5):907-14. doi: 10.1016/j.eururo.2013.04.039. Epub 2013 Apr 30.

PMID:
23669165
20.

Urinary function after radical prostatectomy: a comparison of the retropubic and perineal approaches.

Gray M, Petroni GR, Theodorescu D.

Urology. 1999 May;53(5):881-90; discussion 890-1.

PMID:
10223478

Supplemental Content

Support Center